AQVESME

Agios Pharmaceuticals expects to have eliminated more than 100 research and development roles by the end of 2026, reducing its R&D workforce by over 35%. The shift follows strong growth in mitapivat sales but comes as a key sickle cell disease regulatory decision moves to February 2027, creating a difficult balance between commercial expansion, research capacity and financial discipline.